CN102188498A - Traditional Chinese medicine composition for treating pediatric high fever and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating pediatric high fever and preparation method thereof Download PDFInfo
- Publication number
- CN102188498A CN102188498A CN2011101213209A CN201110121320A CN102188498A CN 102188498 A CN102188498 A CN 102188498A CN 2011101213209 A CN2011101213209 A CN 2011101213209A CN 201110121320 A CN201110121320 A CN 201110121320A CN 102188498 A CN102188498 A CN 102188498A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 208000021760 high fever Diseases 0.000 title abstract 6
- 230000000694 effects Effects 0.000 claims abstract description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000463 material Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005303 weighing Methods 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 25
- 206010020741 Hyperpyrexia Diseases 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 13
- 239000003826 tablet Substances 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 238000012869 ethanol precipitation Methods 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 abstract description 13
- 210000004072 lung Anatomy 0.000 abstract description 12
- 238000001035 drying Methods 0.000 abstract description 2
- 241000081144 Lemmaphyllum carnosum var. drymoglossoides Species 0.000 abstract 2
- 241001648835 Polygonum cuspidatum Species 0.000 abstract 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 235000019659 mouth feeling Nutrition 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 230000002155 anti-virotic effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229940100050 virazole Drugs 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010035737 Pneumonia viral Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000009421 viral pneumonia Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- XABJJJZIQNZSIM-UHFFFAOYSA-N azane;phenol Chemical compound [NH4+].[O-]C1=CC=CC=C1 XABJJJZIQNZSIM-UHFFFAOYSA-N 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating pediatric high fever and a preparation method thereof. The traditional Chinese medicine composition for treating pediatric high fever is mainly prepared from radix pseudostellariae, radix tetrastigme, lepidogrammitis drymoglossoides ching, polygonum cuspidatum leaves and the like. The preparation method comprises the following steps: weighing the radix pseudostellariae, radix tetrastigme, lepidogrammitis drymoglossoides ching, polygonum cuspidatum leaves in percentage by weight, adding water for decocting and concentrating, adding alcohol for precipitation, recovering alcohol, concentrating into extractum, drying, sieving, pelletizing and making proper preparation. The invention has the characteristics that the traditional Chinese medicine composition for treating pediatric high fever is purely natural and has obvious effects on tonifying spleen and lung, dispelling the wind and reducing spitting, clearing away heat and toxic material, especially on various pediatric high fevers; due to adoption of oral administration, the use is convenient, the mouthfeeling is good and the composition is well accepted by a patient; and during clinical use, the composition has good curative effect, short period, low price and no toxic and side effects, thus being satisfactory medicament for pediatric high fever.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation and promptly treat Chinese medicine composition of infantile hyperpyrexia and preparation method thereof.
Background technology
Infantile hyperpyrexia is one of the most common pediatric disease.Children's's physiological and pathological feature is that internal organs are tender and lovely, and shape gas does not fill, adding cold warm can not self-regulated, the breast food can not in case nurse inappropriately, then easily be hindered by pathogenic factor from joint, so, morbidity easily on the pathology, lung is easily got involved, the spleen tending to insufficiency usually, because the spleen lung is the dirty of mothers and sons, female sick son or illness of child viscera affecting mother one of passing influences each other on pathology, and often the lung spleen is with sick.Children's is the body of " pure sun ", YANG often being in excess, in case ill, the easy heat being transformed from excessive YANG of pathogenic factor, easily sensible heat is prosperous, so clinical children's's calentura (card) is maximum.
From the infantile hyperpyrexia etiology and pathogenesis, because of children's's physiology and pathology and adult different, so infantile hyperpyrexia often has following characteristics: 1. easily hold expectorant under the arm: children's's the bottom of heart is tender especially, and exopathogen is violated lung, easily causes impaired depurative descending of lung QI, lose in compress in water Tianjin, be detained in lung, poly-form expectorant, so after the fever of children, easily doublely hold phlegm syndrome under the arm and cough aggravation, wheezing sound in the throat etc. occur.2. easily hold under the arm stagnant: children's's the spleen tending to insufficiency usually, stomach little and a little less than, tolerant few, so after the being invaded by exogenous pathogen, often cause taste to be received and transport imbalance, water paddy instead stagnates, making heating the stagnate card and distension and fullness in the abdomen occurs of being accompanied by dyspepsia of easily holding concurrently, anorexia, even make spleen and stomach function not normal and vomit, have loose bowels etc.3. easily hold under the arm frightened: children's's conscience is had a surplus, being invaded by exogenous pathogen, and facilitation transconversion into heat fire, wind symptom is disturbed the heart, makes heating easily hold under the arm frightened and agitation occurs and cry and scream, and is frightened cautious, even faints from fear.4. easy impairment of YIN impairment of body fluid liquid: children's is owing to " undeveloped infantile YIN ", so easy cloudy impairment of YANG is high: owing to " YANG often being in excess ", it is the heat-transformation fire-transformation that sun is had a surplus again, intimately all can impairment of YIN, so children's sees the card of impairment of YIN impairment of body fluid liquid more and the puckery dryness in the nasal cavity of order occurs, the xerostomia parched lips in heat syndrome, dry pharynx and the pain, thirsty, the few expectorant of dry cough, the few Tianjin of the red no fur of tongue light, constipation due to dry stool, the red .5. that waits of short urination easily holds under the arm wet: damp being a kind of YIN pathogen, deep viscous, taste after all.Because the easiest disease of the spleen and stomach in children characteristics decision children's " wets ".Moistly be stained with greasyly, easily check mechanism of qi, retention of damp leading to blockage of QI, the stagnation of QI is added with heavily wet resistance, deadlocked being difficult to resolve, damp is difficult for speed and goes.So easily doublely during fever of children hold damp syndrome under the arm and limbs to occur sleepy, oppression sensation over the epigastrium and anorexia, the abdominal distention vomiting and nausea, the loose stool is not well, difficulty in urination, greasy fur on tongue or thick greasy etc.Arise now and then, the course of disease is longer, and touching difficulty more.
The medicine commonly used of existing commercially available treatment fever of children has " that quick granule of child ammonia phenol ", " XIAOER QINGRE JIEDU KOUFUYE ", " infantile common cold electuary " etc., its weak point is: one is to use inconvenience, compliance is poor, children's refuses clothes and cries and screams, often because of not enough the affecting the treatment of food dose: the 2nd, there is not preferably etiology and pathogenesis at children's's physiological and pathological feature and infantile hyperpyrexia, there are not dispersing lung-QI and dissipating phlegm, appetizing activating the spleen, resolving depression intestinal stasis relieving, QI flow promoting well, whole adjustment etc., the medication effect is relatively poor.So the exploitation of Chinese medicine composition of the present invention is exactly in order to satisfy the demand of children's's particular patients '.Minimizing improves clinical efficacy and designs the infringement of children's's health.
Summary of the invention
Purpose of the present invention is intended to infantile hyperpyrexia is played fine therapeutical effect, and has advantages such as good effect, the cycle is short, price is low, have no side effect, and is a kind of Chinese medicine composition that the patient takes like a shot.Chinese medicine composition of the present invention mainly is made up of Radix Pseudostellariae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Drymoglossum Herba Drymoglossi, Folium Polygoni Cuspidati etc.The Radix Pseudostellariae function is mended strengthening spleen and lung, supplementing QI for promoting the production of body fluid.Cure mainly the cough due to deficiency of the lung, insufficiency of the spleen lack of appetite, cardiopalmus, palpitation with a distress feeling, edema is quenched one's thirst, and spirit is tired.Be monarch drug in the side; Radix Apioris Fortunei (Radix Lespedezae Buergeri) is flat, mildly bitter flavor, energy heat-clearing and toxic substances removing, dispelling pathogenic wind and eliminating phlegm, promoting blood circulation and stopping pain.Being mainly used in treatment infantile hyperpyrexia convulsions has specially good effect, is ministerial drug in the side; Drymoglossum Herba Drymoglossi is sweet, bitter, cold.The function that dispelling pathogenic wind and eliminating phlegm, heat-clearing and toxic substances removing, cooling blood and dissolving stasis are arranged.Cure mainly lymphadenitis, pulmonary tuberculosis, rheumatic ostalgia, infantile hyperpyrexia, interior traumatic hemorrhage, traumatic injury, external curing pyogenic infections from tumour or sore.The Folium Polygoni Cuspidati hardship, property is flat, the function wind-damp dispelling; Separate pyretic toxicity, cure mainly Fengshi Guanjie pain, venom, dermatitis rhus.The two cooperates the function that all can strengthen heat-clearing and toxic substances removing, and four medicines cooperate and amount to the merit of mending strengthening spleen and lung, dispelling pathogenic wind and eliminating phlegm, heat-clearing and toxic substances removing.
The present invention is according to understanding and the determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs principle of the traditional Chinese medical science to infantile hyperpyrexia, according to traditional Chinese medical science prescription and preparation principle Chinese medicine composition is developed meticulously, realizes by following technical scheme:
The consumption of drug component of the present invention is groped to sum up to draw through the inventor in a large number, and each amounts of components all has curative effect preferably in following ranges, and medicine of the present invention contains
331～999 parts of 331～999 parts of Radix Apioris Fortunei (Radix Lespedezae Buergeri)s of Radix Pseudostellariae
220～496 parts of 331～999 parts of Folium Polygoni Cuspidatis of Drymoglossum Herba Drymoglossi
Preferable range is:
498～998 parts of 331～999 parts of Radix Apioris Fortunei (Radix Lespedezae Buergeri)s of Radix Pseudostellariae
250～350 parts of 331～666 parts of Folium Polygoni Cuspidatis of Drymoglossum Herba Drymoglossi
Optimum weight part is:
666 parts of 333 parts of Radix Apioris Fortunei (Radix Lespedezae Buergeri)s of Radix Pseudostellariae
282 parts of 333 parts of Folium Polygoni Cuspidatis of Drymoglossum Herba Drymoglossi
Technical problem to be solved by this invention is to realize by following technical scheme.Be characterized in that with Radix Pseudostellariae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Drymoglossum Herba Drymoglossi, Folium Polygoni Cuspidati etc. be the medicine that raw material is made.The Chinese medicine composition of this treatment infantile hyperpyrexia, it is characterized in that it by following main materials be component form or by the water extract of following main materials as active component with pharmaceutically acceptable additives are formed or be made up of as active component and pharmaceutically acceptable additives the alcohol extract of following main materials.The present invention has the merit of mending strengthening spleen and lung, dispelling pathogenic wind and eliminating phlegm, heat-clearing and toxic substances removing by scientific combination, development meticulously, also has the effect of strengthening vital QI to eliminate pathogenic factors concurrently, and is particularly remarkable to all kinds of infantile hyperpyrexia effects.
Medicine of the present invention can adopt the Chinese medicine preparation conventional method to be prepared into any pharmaceutically useful conventional formulation.After for example these crude drug can being crushed into powder, mix homogeneously is made powder and is taken after mixing it with water; Also can be with these medicines decocting together, the condensed water decocting liquid is made oral liquid then; But, preferably crude drug Radix Pseudostellariae, Radix Apioris Fortunei (Radix Lespedezae Buergeri), Drymoglossum Herba Drymoglossi, Folium Polygoni Cuspidati are carried out special distillation extraction, but this can not limit protection scope of the present invention in order to make each crude drug of this medicine better bring into play drug effect.
Described pharmaceutically receptible additives are following one or more: as glycerol, gelatin, Polyethylene Glycol, propylene glycol, dextrin, ethanol, dried starch, citric acid, sodium bicarbonate, ethyl hydroxybenzoate, tartaric acid, lecithin, sodium lauryl sulphate etc.
Its dosage form is a said dosage form on any pharmaceutics, as syrup, granule, capsule, tablet etc.; Described capsule is common capsule, effervescent capsule or other various suitable capsules; Described tablet is common tablet, effervescent tablet, dispersible tablet or other various suitable tablets.With suitable coating material coating or do not carry out coating.
2. effectively stable for safety of medicine of the present invention is described better, the inventor is as follows with effect experiment and clinical effect interpretation of result:
2.1 laboratory animal: white mice, body weight 18～22g; Rat, body weight 150～200g; Rabbit, body weight 18.6～21.3kg is available from Zhejiang medical courses in general institute Experimental Animal Center.
2.2 main agents
Acetic acid (analytical pure), 2,2, 4-dinitrophenol (analytical pure), 10% Ovum Gallus domesticus album solution, dexamethasone injection, picric acid (labelling is used), reagent is available from Hangzhou chemical company.
2.3. experiment equipment: platform scale, thermometer, syringe, rabbit fixed mount, mouse cage, thermostat water bath, stopwatch, beaker etc.
2.4. experimental technique:
2.4.1 the present invention is to the refrigeration function of fever in rabbit
Adopt 2,2, 4-dinitrophenol 2% aqueous solution produces the fever in rabbits pathological model.Get 2 of healthy rabbits, the labelling of weighing, fixing.Survey the anus temperature respectively 2 times, with average as normal body temperature.From first, second two rabbit back subcutaneous injections 2,2, 4-dinitrophenol 2% aqueous solution 30mg/kg treats that fervescence surpasses 1 ℃ and (needs 30～40min) approximately, administration in the following manner respectively: first rabbit (heating rabbit): intraperitoneal injection of saline 0.15ml/kg; Second rabbit (heating rabbit): lumbar injection medicinal liquid 0.15ml/kg.After the administration 30,60,90,120min tests the anus temperature respectively.The results are shown in Table 1.
The refrigeration function experimental result of table 1 pair rabbit/℃
The fervescence of administration group as can be seen from Table 1 is lower than 1.4 ℃ of normal saline matched groups, illustrates that this medicine is obvious to the fever in rabbit refrigeration function.
2.4.2 medicine of the present invention is to the inhibitory action of rat paw edema
50 of experimental technique and animal grouping female sd inbred rats are divided into 5 groups at random, and the rat foot causes inflammation with carrageenin; Medicine of the present invention low (0.3g/kg), in (0.6g/kg), high dose (1.2g/kg) group, compare (1.4/kg) with cortisone acetate, normal saline matched group (with the capacity normal saline).Gastric infusion, successive administration 7 days, once a day.The results are shown in Table 2.
Table 2 pharmaceutical composition of the present invention is to the inhibitory action of rat paw edema
Annotate: * * compares P＜0.01 with model control group with the control drug group
As can be seen from Table 2, Chinese drug-treated group and normal saline group relatively have tangible antiinflammatory action, but its effect is lower than Dexamethasone group.The result shows that medicine high dose of the present invention has obvious inhibitory action to rat paw edema, though in, low dose group has the trend that alleviates rat paw edema, difference does not have significance (table 2).
2.4.3 medicine of the present invention is tested the antitussive of mice:
30 of Kunming mouses, male and female dual-purpose, body weight 18～20g divide 3 groups at random. and 10 every group, irritate stomach respectively and give drug solution of the present invention, high dose 20g/kg, low dose group matched group 10g/kg; Capacity water such as matched group, once a day, continuous three days.After the last administration 30 minutes, by only Mus being put into glass bell jar, put into long 10cm from bell jar is suitable for reading, wide 1.5cm is the filter paper bar still, drips 0.5ml ammonia above, airtight, the cough latent period of mice is whenever changed a Mus behind the observation suction ammonia, changes a filter paper bar, whenever all drip 0.5ml ammonia, experimental result sees Table 3.
Table 3 medicine of the present invention is to the antitussive action of mice
With matched group than * P＜0.05 * * P＜0.01
T check between group: high low dose group antitussive effect all has the significance meaning, P＜0.01 and P＜0.05.2.4.4 medicine of the present invention is to the experiment of eliminating the phlegm of mice: 30 of Kunming mouses, body weight 18～20g divide 3 groups at random.Every group 10, irritate the solution that stomach gives the asthma capsule respectively, high dose 20g/kg. low dose group matched group 10g/kg; Capacity water such as matched group, once a day, continuous three days, after the last administration 30 minutes, every Mus lumbar injection 0.5% phenol red 0.5ml was after half an hour.Take off cervical vertebra and put to death mice, face upward the position and be fixed on the operation plate, cut off neck center skin, separate trachea, under larynx injection needle is inserted trachea, ligation is fixed, and draws 5% carbonate ammonia natrium solution 0.5ml. flushing respiratory tract three times with syringe.Amount to flushing three times, totally nine times.Each flushing liquor is put into test tube, with 751 ultraviolet spectrophotometer colorimetrics.Experimental result sees Table 4.
Table 4: medicine of the present invention is to the phlegm-dispelling functions of mice
With matched group than * P＜0.05 * * P＜0.01
T check between group, high low dose group is eliminated the phlegm all has the significance meaning (P＜0.01 and P＜0.05)
2.4.5 medicine of the present invention is to the extracorporeal antivirus effect effect
(1) each trial drug is measured through the CPE method the maximal non-toxic concentration of Vero cell, and all less than 0.04mg/ml (1: 100), in formal drug test, then the medicine of employing＜0.04mg/ml carries out the extracorporeal antivirus effect test,
(2) each trial drug causes the cytopathic inhibitory action of Vero to HSV-I virus, and RSV virus is caused the cytopathic inhibitory action of Hep-2.Result of the test is as shown in table 5.
The different trial drug extracorporeal antivirus effect effects of forming of table 5 the present invention
Annotate: "-" clothing shows that cell does not have pathological changes: " 1+ " about 25% cell generation pathological changes, " 2+ " about 50% cell generation pathological changes, " 3+ " about 75% cell generation pathological changes, " 4+ " about 100% cell generation pathological changes.
2.4.6 test to the protective effect of influenza virus induced mice pneumonia.
Get 100 of healthy mices, be divided into virazole positive drug matched group at random, the high and low dose group of trial drug of the present invention, and model control group and normal control group, 20 every group, male and female half and half.Get 10 times of LD
5O measures (10TCLD
5O) collunarium infecting mouse pulmonary, the normal control group sucks normal saline, 30ul/ only, infected back 2 hours, and gave every mice trial drug 20 of the present invention, 40mg/kg respectively, virazole 20mg/kg, im, model control group, normal control group then all give the 0.5ml normal saline, administration every day 3 times, successive administration 5 days.Begin to observe 15 days continuously from administration, write down death toll and death time behind the mouse infection influenza virus every day, calculate dead protective rate as follows and prolong vital rates with the dead sum of every treated animal in 15 days:
Dead protective rate (%).(model group mortality rate-experimental group mortality rate);
Prolong vital rates (%): (experimental group on average life number of days-model group on average life number of days)/(model group is life number of days on average) * 100%,
It is as shown in the table for result of the test, gives the trial drug of the present invention of high and low dose after the mouse infection virus, all can reduce the animal dead rate, prolongs average life number of days, and along with drug dose increases, effect increases; And the model control group animal obviously became thin after 4 days, dyspnea, and beginning is dead.Compare with model control group, the high and low dose of medicine of the present invention can significantly reduce animal dead rate (P＜0.05), and is better than virazole.
Table 6 trial drug is to the protective effect of mice viral pneumonia
Compare * P＜0.05 with model group
Experiment conclusion:, confirm that medicine of the present invention has tangible heat clearing away, antiinflammatory, cough-relieving and phlegm-dispelling functions to mice by above experiment.And remarkable effect is arranged to extracorporeal antivirus effect with to the protection of mice viral pneumonia.
2.4.5 clinical verification:
With Zhejiang Province's first hospital clinical checking, its criterion: the three days clinical symptoms of taking medicine are partly alleviated and are produce effects, and the three days clinical symptoms of taking medicine disappearance person substantially are recovery from illness.By to 500 routine administration clinical observations, in the our medicine treatment 2 days, body temperature is reduced to normal person fully and is accounted for 86.2%, and the disease cure rate is 47.8%, and in the our medicine treatment 3 days, the disease total effective rate is 97.6%.Evident in efficacy, there is not any untoward reaction.
The present invention is by long term studies and practice, reasonable recipe, technology advanced person, the speciality that give full play to the Chinese medicine good effect, has no side effect, be a kind of good and cheap, consumption is little, instant effect, curative effect height, the gratifying clear infantile hyperpyrexia medication that is easy to carry and uses.
The specific embodiment
Embodiment 1:
Take by weighing Radix Pseudostellariae 200 gram, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 300 grams, Drymoglossum Herba Drymoglossi 150 grams, Folium Polygoni Cuspidati 150 grams by weight percentage, decoct with water, concentrate, add ethanol precipitation, reclaim ethanol, be condensed into the extractum shape, dry, sieve, granulate, make suitable preparation.
Embodiment 2
Tablet takes by weighing Radix Pseudostellariae 300 grams, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 500 grams, Drymoglossum Herba Drymoglossi 250 grams, Folium Polygoni Cuspidati 150 grams by weight percentage, gets extractum with example 1 legal system, is ground into fine powder, with the appropriate amount of auxiliary materials mixing, granulate, and drying, tabletting, promptly.
Embodiment 3:
Capsule takes by weighing Radix Pseudostellariae 250 grams, Radix Apioris Fortunei (Radix Lespedezae Buergeri) 500 grams, Drymoglossum Herba Drymoglossi 250 grams, Folium Polygoni Cuspidati 250 grams by weight, and get extractum with example 1 legal system and make fine powder and appropriate amount of auxiliary materials mixing, the encapsulating capsule, packing is promptly.
Characteristics of the present invention are that it is All Pure Nature pharmaceutical preparation, have the merit of mending strengthening spleen and lung, dispelling pathogenic wind and eliminating phlegm, heat-clearing and toxic substances removing, and are particularly remarkable to all kinds of infantile hyperpyrexia effects; Adopt peroral dosage form, easy to use, mouthfeel is good, and the patient easily accepts; In clinical use good effect, the cycle is short, price is low, have no side effect, and is a kind of gratifying clear infantile hyperpyrexia medication.
Claims (5)
1. Chinese medicine composition for the treatment of infantile hyperpyrexia, it is characterized in that it by following main materials be component form or by the water extract of following main materials as active component with pharmaceutically acceptable additives are formed or be made up of as active component and pharmaceutically acceptable additives the alcohol extract of following main materials: the consumption of drug component of the present invention is groped to sum up to draw through the inventor in a large number, and each amounts of components all has curative effect preferably in following ranges.
2. medicine of the present invention contains
331～999 parts of 331～999 parts of Radix Apioris Fortunei (Radix Lespedezae Buergeri)s of Radix Pseudostellariae
220～496 parts of 331～999 parts of Folium Polygoni Cuspidatis of Drymoglossum Herba Drymoglossi
Preferable range is:
498～998 parts of 331～999 parts of Radix Apioris Fortunei (Radix Lespedezae Buergeri)s of Radix Pseudostellariae
250～350 parts of 331～666 parts of Folium Polygoni Cuspidatis of Drymoglossum Herba Drymoglossi
Optimum weight part is:
666 parts of 333 parts of Radix Apioris Fortunei (Radix Lespedezae Buergeri)s of Radix Pseudostellariae
288 parts of 333 parts of Folium Polygoni Cuspidatis of Drymoglossum Herba Drymoglossi.
3. preparation of drug combination method according to claim 1 is characterized in that comprising the steps:
Take by weighing each raw material by formula proportion, said medicine is cleaned, dried in the shade, section or broken decocts with water, concentrates, adds ethanol precipitation, reclaims ethanol, is condensed into the extractum shape then, and is dry, sieve, granulate, and makes suitable preparation.
4. Chinese medicine composition according to claim 1 is characterized in that: the described additives of pharmaceutically accepting are following one or more: as glycerol, gelatin, Polyethylene Glycol, propylene glycol, dextrin, dried starch, ethylparaben, tartaric acid, citric acid, sodium bicarbonate, lecithin, sodium lauryl sulphate.
5. Chinese medicine composition according to claim 1 is characterized in that: its dosage form is a said dosage form on any pharmaceutics, as effervescent granule electuary, capsule, tablet etc.; Described capsule is common capsule, effervescent capsule or other various suitable capsules; Described tablet is common tablet, effervescent tablet, dispersible tablet or other various suitable tablets; With suitable coating material coating or do not carry out coating.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110121320 CN102188498B (en) | 2011-05-10 | 2011-05-10 | Traditional Chinese medicine composition for treating pediatric high fever and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110121320 CN102188498B (en) | 2011-05-10 | 2011-05-10 | Traditional Chinese medicine composition for treating pediatric high fever and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102188498A true CN102188498A (en) | 2011-09-21 |
| CN102188498B CN102188498B (en) | 2013-04-24 |
Family
ID=44597933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110121320 Expired - Fee Related CN102188498B (en) | 2011-05-10 | 2011-05-10 | Traditional Chinese medicine composition for treating pediatric high fever and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102188498B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186812A (en) * | 2018-02-06 | 2018-06-22 | 浙江中医药大学 | Application of the Lemna paucicostata in anti-hyperpyretic convulsion drug is prepared |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474355A (en) * | 2009-02-01 | 2009-07-08 | 高树英 | Method for preparing Chinese medicine for treating heat induced by children's deficiency of qi |
-
2011
- 2011-05-10 CN CN 201110121320 patent/CN102188498B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474355A (en) * | 2009-02-01 | 2009-07-08 | 高树英 | Method for preparing Chinese medicine for treating heat induced by children's deficiency of qi |
Non-Patent Citations (1)
| Title |
|---|
| 江苏新医学院: "《中药大辞典》", 30 June 1986, article "太子参、虎杖等" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108186812A (en) * | 2018-02-06 | 2018-06-22 | 浙江中医药大学 | Application of the Lemna paucicostata in anti-hyperpyretic convulsion drug is prepared |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102188498B (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1899543B (en) | External plaster for treating child fever and preparing method | |
| CN100450540C (en) | External plaster for treating child cold type cough and preparing method | |
| CN102475835B (en) | Pharmaceutical composition for treating common cold or cough caused by common cold in children and preparation method thereof | |
| CN102319294B (en) | Double-vanilla preparation and preparation method thereof | |
| CN105998599A (en) | Traditional Chinese medicine composition for treating viral respiratory tract infection and preparation method thereof | |
| CN103990025B (en) | Traditional Chinese medicine for treating children cough variant asthma and preparation method of traditional Chinese medicine | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN102188498B (en) | Traditional Chinese medicine composition for treating pediatric high fever and preparation method thereof | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN1814194B (en) | Chinese-western medicine composition for treating infant's common cold and preparation method thereof | |
| CN101278981A (en) | Medicament for treating upper respiratory tract infection in children and preparation method thereof | |
| CN104840737B (en) | Chinese medicine composition with qi invigorating and lung moistening effect and its preparation method and application | |
| CN103340986B (en) | Traditional Chinese medicine enema for treating hand-foot-and-mouth disease of children | |
| CN102228633A (en) | Traditional Chinese medicine for treating blood heat and toxic type nosebleed of children and preparation method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN101632777A (en) | Chinese medicinal composition for clearing away heat and toxic material, dispersing food and freeing bowels and preparation method thereof | |
| CN104887775A (en) | Traditional Chinese medicine preparation for treating neonatal scleredema and preparation method therefor | |
| CN101279056B (en) | Children's antipyretic granule | |
| CN103041362A (en) | Drug for treating rheumatism and rheumatoid and preparation method thereof | |
| CN102302688A (en) | Traditional Chinese medicine used for treating influenza caused by damp toxin, and preparation method thereof | |
| CN106491692A (en) | A kind of coldrex | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN100482264C (en) | Shenling Chinese medicine preparation for strengthening body resistance | |
| CN103768425B (en) | A kind of Chinese medicine composition treating infant upper respiratory tract infection and preparation method and application | |
| CN105288202A (en) | Pharmaceutical composition for curing infantile cough |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG MEDICAL COLLEGE Free format text: FORMER OWNER: YANG XIONGZHI Effective date: 20130306 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20130306 Address after: 315100 Zhejiang city of Ningbo province Yinzhou District County Road No. 888 east section of Zhejiang Pharmaceutical College Applicant after: Zhejiang Pharmaceutical College Address before: 315100 Zhejiang city of Ningbo Province Higher Education Park East Yinxian Avenue No. 888 Zhejiang Pharmaceutical College Applicant before: Yang Xiongzhi |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160414 Address after: 311402 No. 89 Golf Road, Fuyang District, Zhejiang, Hangzhou Patentee after: Hangzhou Huawei Pharmaceutical Co., Ltd. Address before: 315100 Zhejiang city of Ningbo province Yinzhou District County Road No. 888 east section of Zhejiang Pharmaceutical College Patentee before: Zhejiang Pharmaceutical College |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130424 Termination date: 20180510 |